RapidAI Secures FDA Clearance for Five Advanced Medical AI Imaging Modules
San Mateo-based medical artificial intelligence company RapidAI announced on November 25, 2025, that it has received U.S. Food and Drug Administration clearance for five innovative imaging modules designed to transform neurology and vascular care delivery. The regulatory milestone represents a significant expansion of the company’s Rapid Enterprise Platform, positioning the firm as a comprehensive solution provider for deep clinical intelligence across hospital systems.
The newly cleared modules include Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement. Each technology addresses specific clinical challenges in neurological and cardiovascular imaging, offering automated analysis capabilities that reduce radiologist workload while improving diagnostic precision.
RapidAI FDA Clearance Enhances Stroke Detection Capabilities
The company’s Rapid LMVO module provides complete brain coverage across anterior, posterior, basilar, and distal territories on CT angiography scans. This advancement extends the company’s leadership in ischemic stroke detection, offering clinicians comprehensive visualization tools for rapid assessment. Combined with existing perfusion and non-contrast modules, the platform delivers validated analysis across the entire stroke care continuum.
Rapid DeltaFuse introduces automated alignment and co-registration of serial non-contrast head CT scans, enabling visualization of subtle intracranial changes including hemorrhages, masses, and ventricular alterations. Clinical studies demonstrate that this technology reduces radiologist comparison time by over 36 percent, directly addressing cognitive burden concerns in radiology departments.
Deep Clinical Intelligence Transforms Vascular Disease Management
The Rapid Aortic module analyzes any computed tomography scan containing aortic imagery, including non-contrast and post-treatment studies. The system identifies and tracks pathology from the aortic arch to the iliac arteries, delivering guideline-based measurements with consistent, reader-independent results. Automated three-dimensional reconstruction capabilities support surgical planning while longitudinal comparison tools simplify surveillance protocols.
Rapid MLS detects and quantifies suspected midline shift with a mean absolute error of just 0.8 millimeters, providing objective visualization for this critical brain injury indicator. Meanwhile, Rapid OH identifies suspected obstructive hydrocephalus through cerebrospinal fluid accumulation detection, generating alerts in under one minute to expedite treatment decisions. The module qualifies for the Centers for Medicare and Medicaid Services New Technology Add-on Payment, underscoring its clinical and economic value.
Market Position Strengthens Through Regulatory Validation
RapidAI CEO Karim Karti emphasized the company’s commitment to developing algorithms that extend beyond simple disease triage. The executive, who previously served as President and CEO of GE Healthcare Imaging, stated that the clearances enable radiologists to practice at the top of their professional capabilities while reducing cognitive burden. The company’s approach focuses on supporting both acute treatment decisions and long-term patient management strategies.
All five modules integrate fully into the Rapid Edge Cloud, the company’s cloud-first information technology platform with on-premises capabilities ensuring service continuity during network disruptions. The technologies also connect seamlessly with Rapid Navigator Pro, the firm’s next-generation radiology solution, along with mobile and web applications. This integration creates unified workflows across picture archiving and communication systems, electronic health records, and reporting platforms.
Clinical Validation Supports Global Healthcare Adoption
RapidAI currently serves more than 2,500 hospitals across over 100 countries, with the platform supported by 700 clinical studies. The company’s research contributions include investigations that influenced national stroke treatment guidelines, demonstrating real-world clinical impact beyond technological innovation.
Dr. Kiran Nandalur, Medical Director at Corewell Health Radiology, noted that the automated calculation and visualization capabilities enable radiologists to concentrate on clinical judgment rather than manual data manipulation. This workflow optimization allows medical professionals to allocate more time to patient care decisions while maintaining diagnostic accuracy.
The November 25 announcement arrives as healthcare systems increasingly seek artificial intelligence solutions that address operational efficiency challenges while improving patient outcomes. The RapidAI FDA clearance positions the company to capitalize on growing demand for validated clinical decision support tools in imaging departments facing workforce pressures and expanding case volumes.
Industry observers note that the comprehensive nature of the platform, spanning both acute and chronic care applications, differentiates the offering in a competitive medical AI market. The regulatory validation provides hospitals with confidence in deploying these technologies within existing infrastructure while meeting compliance requirements.
